- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. The NICE-Wide Prioritisation board met on 15 September 2025 and concluded that an evaluation would not be appropriate for this product. The board confirmed the clear rationale being due to the existing clinical guideline NG18 Overview | Diabetes (type 1 and type 2) in children and young people: diagnosis and management | Guidance | NICE recommending named pharmacological treatments and agreed that it would be appropriate to update the guideline following regulatory approval. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12249
Email enquiries
If you have any queries please email [email protected]
Related links
For further information on how we select topics for development, please see our page about prioritising our guidance topics